Scisparc Ltd（SPRC）股票分析SPRCScisparc Ltd

Scisparc Ltd, formerly Therapix Biosciences Ltd, is an Israel-based pharmaceutical company committed to creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The Company is engaged in drug development programs based on repurposing cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), obstructive sleep apnea (OSA) and pain; THX-130 for the treatment of mild cognitive impairment (MCI) and traumatic brain injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

SciSparc Ltd. is not a good buy right now due to its significant recent losses and negative financial indicators. The stock has dropped 91.35% year-to-date and has a current price of $1.09, which is far below its historical performance. Additionally, the RSI is extremely low at 5.451, indicating that the stock is oversold and may continue to decline. The company also reported a net margin of -2041.65% in Q2 2025, highlighting severe profitability issues. The main risk is the ongoing decline in stock price, with a 5-day change of -35.88%.